When will the patents on PIMOZIDE expire, and when will PIMOZIDE go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novitium Pharma	PIMOZIDE	pimozide	TABLET;ORAL	219897-001	Apr 13, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ph Health	PIMOZIDE	pimozide	TABLET;ORAL	204521-002	Sep 28, 2015	AB	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novitium Pharma	PIMOZIDE	pimozide	TABLET;ORAL	219897-002	Apr 13, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ph Health	PIMOZIDE	pimozide	TABLET;ORAL	204521-001	Sep 28, 2015	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: June 9, 2026

Pimozide is an older, off-patent antipsychotic (typical oral use in Tourette syndrome and schizophrenia). Investment exposure is driven by (1) residual brand inventory economics in the US, (2) how much supply is constrained by narrow formulary presence and older manufacturing processes, and (3) the timing and likelihood of generic entry (or renewed litigation risk) versus any remaining unexpired US exclusivity attached to specific label indications or formulation/packaging.

What matters most for investors: pimozide’s commercial upside is capped by the age of the asset class and the expected absence of meaningful new exclusivity. Real opportunities skew toward niche supply, lifecycle extensions via new formulations (if any are approved), and distribution/channel economics rather than breakthrough clinical/IP re-rating.

What is pimozide’s FDA status and Orange Book listing status?

Executive answer: Pimozide is an FDA-approved drug with a long-established generic ecosystem. The practical investment question is whether any current marketed strengths and dosage forms still have branded Orange Book-listed exclusivities/patents, or whether generic products already fully cover demand.

Which indications define the commercial footprint (Tourette syndrome vs schizophrenia)?

Pimozide labeling historically targets:

Tourette syndrome (patients who do not respond adequately to standard therapies)
Schizophrenia (less common in modern practice than newer antipsychotics)

Investment implication: Tourette demand is smaller and more guideline-sensitive. Any reimbursement or formulary churn tends to move volume quickly among low-cost generics.

What is the current market structure implied by an “older” antipsychotic?

For older molecules like pimozide, the US market typically has:

Multiple generic NDA/ANDA products supplying each strength
Limited brand premium unless supply disruptions occur
Low pricing power and high competitive sensitivity

How does FDA labeling affect substitution and tender dynamics?

Pimozide’s safety profile (QT prolongation and other risks) is a key barrier to broad switching among prescribers who are cautious with older antipsychotics. This can slow substitution into some segments, but it usually does not prevent generics once ANDA products are established.

When does pimozide lose exclusivity and what are the expected patent expiration timelines?

Executive answer: For pimozide, exclusivity and core composition claims are generally well beyond typical patent life. Investment exposure focuses on whether any secondary patents still exist on file for specific dosage forms or packaging, rather than primary active ingredient protection.

How to think about exclusivity in older small-molecule assets

For assets first approved decades ago, the relevant exclusivity concepts that could still matter are typically:

Remaining US patents listed in the Orange Book for particular strengths/dosage forms
Any recent supplemental listings (rare for a mature genericized molecule)

What generic entry risks exist for pimozide after potential ANDA filings?

For mature products:

The “first generic” risk is usually past
The ongoing risk is more about carve-outs (specific strengths, manufacturing sites, or regulatory exclusivity blocks)

What patents protect pimozide in the US and how strong is the remaining patent estate?

Executive answer: The remaining US patent estate for pimozide is expected to be weak or immaterial in most economic scenarios, because the molecule itself is old and likely fully genericized. The only value-relevant patent hooks would be formulation, method-of-use, or manufacturing patents that still have enforceable life.

Patent estate mapping: what to check in the Orange Book record

For pimozide, any still-active listings would typically fall into one or more buckets:

Composition-of-matter for active ingredient or salts/polymorphs
Formulation patents (tablet coating, excipients, dissolution control)
Method-of-use (specific patient population or regimen)
Packaging or device-adjacent claims (less common for oral solids)

How strong is enforceability risk versus generics?

Practical enforcement strength in a mature asset:

Even if a patent exists, generics often design around formulation features
Litigations historically cluster around late-expiring formulation or method claims, not around the underlying drug

How many formulation patents cover pimozide tablets and what delivery systems are protected?

Executive answer: Any formulation protection, if it exists, is the only plausible basis for near-term investment advantage. For pimozide, formulation-specific claims are likely limited because the drug is established and generics already exist in the market.

What dosage forms matter economically

Investment impact is strength-specific:

Tablet strengths drive tender and substitution economics
If only some strengths have active listings, those strengths may have partial supply/entry friction

What manufacturing method patents could affect supply?

If manufacturing method patents exist, they tend to affect:

Site transfer approvals and validation packages
Design-around feasibility for process parameters

What method-of-use patents exist for pimozide in Tourette syndrome or schizophrenia?

Executive answer: Method-of-use protection can be relevant for older antipsychotics if tied to a narrower indication subset. For pimozide, the economic likelihood of meaningful remaining method-of-use life is low.

How method-of-use claims translate into real-world generic barriers

Even when method-of-use patents exist:

ANDA products can typically be labeled for non-patented uses
Distribution strategies can route demand to non-barred indications
Litigation risk usually translates into limited delay rather than long-term exclusivity unless multiple patents block label carve-outs

What Paragraph IV litigation or patent challenges affect pimozide generics?

Executive answer: For an old molecule like pimozide, large-scale Paragraph IV dynamics are usually already resolved. The investable issue is whether any later-cycle litigation exists around formulation or method claims still listed.

How to evaluate litigation-driven valuation

Key litigation signals:

Whether a challenger sought a carve-out for certain claims
Settlement terms that include market delay, exclusivity transfer, or “at-risk” launch scheduling
Whether courts entered claim construction that materially changes design-around viability

Do biosimilars apply to pimozide, and what is the analog risk for this small molecule?

Executive answer: Biosimilars do not apply to pimozide. The relevant competition is small-molecule generics, not biologic follow-ons.

How does pimozide compare with competing antipsychotics for investment defensibility?

Executive answer: The investable comparison is not between antipsychotics as therapeutic equivalents but between IP duration and pricing power. Newer antipsychotics offer stronger defensibility via branded clinical positioning and recent patent life. Pimozide’s defensibility is supply-chain and channel-managed rather than IP-led.

What to benchmark against

Pricing trajectory versus older generics in the same neuropsychiatric space
Formulary position and prior authorization intensity
Safety-driven switching friction (QT risk can increase conservative prescribing)

Where pimozide can retain volume

Even with generics, mature drugs can hold volume when:

Prescribers keep stable regimens
Patients tolerate existing therapy
Hospitals prefer legacy protocols

This is a distribution and preference story, not a patent story.

What commercial fundamentals drive pimozide revenue exposure in the next 24 months?

Executive answer: Revenue exposure is driven by:

generic price compression,
stability of supply and manufacturing site approvals,
whether any label/market access restrictions alter prescribing behavior.

How to model the revenue ceiling

A practical investment model for mature genericized small molecules:

Start with baseline volume (prescriber and patient population stable but shrinking slowly)
Apply pricing trend based on generic class dynamics
Add supply premium effects only if there is a supply disruption risk

What tends to move pimozide demand

Tourette syndrome treatment guidance changes
CNS safety perceptions and QT-risk management protocols
Payer formulary changes and switching policies

What manufacturing and supply-chain risks affect pimozide competition and pricing?

Executive answer: For older oral products, the biggest swing factor is not IP. It is manufacturing reliability, capacity allocation at the GMP level, and regulatory constraints affecting specific strengths.

What to look for in production risk

Single-site dependence for certain strengths
Batch failures or recurring CMC issues
Change-control bottlenecks that delay replenishment

Why supply disruption matters more than patents

In a generic market, price can decouple from IP:

If supply tightens, price rises quickly across the category
If supply improves, price drops quickly

What licensing deals or pipeline assets could extend pimozide’s value?

Executive answer: The highest-probability licensing/value-extension channel is not new composition claims on pimozide itself. It is:

formulation lifecycle programs (new release profile, new fixed-dose combinations if ever pursued)
branded relaunch via improved risk management or patient support tied to compliance

For pimozide specifically, the economic probability of a material licensing re-rate is low unless a contemporary formulation or new controlled-release concept is active in regulatory filings and markets.

Key Takeaways

IP-led upside is limited. For pimozide, patent duration is likely far beyond meaningful remaining life, making exclusivity and composition claims largely non-driving factors.
Investment is a supply-and-channel bet. Pricing power depends on generic competition intensity and manufacturing reliability for particular strengths.
Litigation is likely not a primary catalyst. Large Paragraph IV dynamics for mature assets are typically already settled; remaining value would come from any late-cycle formulation/method patents still active in the Orange Book.
Market fundamentals dominate. Tourette and schizophrenia demand are sensitive to payer and prescriber behavior; QT-risk perception can influence switching but usually does not sustain premium pricing versus low-cost generics for long.
Best-case scenario: episodic supply tightness or a targeted lifecycle reformulation could create short-lived pricing relief, not a long-duration monopoly.

FAQs

1) What is the Orange Book status of pimozide generics and which patents remain listed today?
Answer: The key is whether any pimozide strengths still show active Orange Book patents/exclusivities tied to formulation, method-of-use, or packaging. The asset’s investment relevance is confined to those remaining listings rather than the original active ingredient.

2) What generic entry risks exist for pimozide in the US for specific tablet strengths?
Answer: The primary risks are strength-specific: if only some strengths have active barriers (patents or labeling carve-outs), generic entry can be delayed for those SKUs even when other strengths are fully stocked.

3) Does pimozide have method-of-use exclusivity that could block label carve-outs for generics?
Answer: Method-of-use blocking is usually short-lived in mature drugs and tends to resolve via carve-outs or settlements that shift market entry by months rather than years.

4) Are there any formulation barriers that would slow pimozide ANDA approvals?
Answer: If formulation-specific patents or complex CMC requirements exist, they can slow site readiness or trigger design-around work. In practice for older drugs, these barriers are usually secondary to established generic manufacturing.

5) How does pimozide’s QT-risk profile affect its formulary and switching economics?
Answer: QT concerns can reduce prescriber willingness to switch, which can slow substitution in segments with conservative protocols. It usually does not eliminate generic competitiveness once multiple low-cost suppliers are established.

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA. Drugs@FDA. U.S. Food and Drug Administration.
FDA. FDA Labeling and Safety Information for Pimozide (current prescribing information). U.S. Food and Drug Administration.

PIMOZIDE Drug Patent Profile

Which patents cover Pimozide, and when can generic versions of Pimozide launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pimozide

AI Deep Research

Questions you can ask:

Summary for PIMOZIDE

US Patents and Regulatory Information for PIMOZIDE

Pimozide Investment Scenario and Patent-Fundamentals Analysis: FDA Status, Exclusivity, Generic/Biosimilar Risk, and Market Economics